Andy Crockett, KalVista Pharmaceuticals CEO

KalVista re­ports PhI­II suc­cess of on-de­mand, oral hered­i­tary an­gioede­ma drug as it seeks to chal­lenge in­jecta­bles

KalVista Phar­ma­ceu­ti­cals’ oral med­i­cine for hered­i­tary an­gioede­ma helped re­lieve at­tack symp­toms as­so­ci­at­ed with the dis­ease sub­stan­tial­ly faster than place­bo in a late-stage study, set­ting the com­pa­ny up to sub­mit for an FDA ap­proval this year.

In hered­i­tary an­gioede­ma, or HAE for short, peo­ple ex­pe­ri­ence se­vere swelling at­tacks. Cur­rent­ly, the at­tacks are treat­ed with in­jectable med­i­cines such as Take­da’s Fi­razyr, but KalVista hopes its pill can pro­vide an eas­i­er and po­ten­tial­ly quick­er op­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.